Suchergebnisse - "Kerstein, David"

PubPharm (14)

1

Effect of severe renal impairment on the pharmacokinetics of brigatinib

enthalten in: Investigational new drugs | 2021

von Gupta, N. | Hanley, M. | Kerstein, D. | +4

2

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer

enthalten in: Clinical pharmacokinetics | 2021

von Gupta, N. | Wang, X. | Offman, E. | +5

3

Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer : Exposure-Response Analyses of Pivotal ALTA Study

enthalten in: CPT: pharmacometrics & systems pharmacology | 2020

von Gupta, N. | Wang, X. | Offman, E. | +6

ErratumIn: CPT Pharmacometrics Syst Pharmacol. 2021 Sep;10(9):1119-1122. - PMID 34414680

4

Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2020

von Ng, T. | Narasimhan, N. | Gupta, N. | +3

CommentIn: J Thorac Oncol. 2020 Jul;15(7):1100-1102. - PMID 32593441

5

Brigatinib in Crizotinib-Refractory ALK+ NSCLC : 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2020

von Huber, R. | Hansen, K. | Paz-Ares Rodríguez, L. | +15

6

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers

enthalten in: Clinical pharmacology in drug development | 2020

von Tugnait, M. | Gupta, N. | Hanley, M. | +5

7

Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study

enthalten in: Journal of medical economics | 2019

von Kawata, A. | Lenderking, W. | Eseyin, O. | +5

8

Patient-reported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA)

enthalten in: Future oncology (London, England) | 2019

von Lenderking, W. | Lin, H. | Speck, R. | +5

9

The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers

enthalten in: Clinical pharmacology in drug development | 2019

von Tugnait, M. | Gupta, N. | Hanley, M. | +5

10

Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer

enthalten in: Current medical research and opinion | 2019

von Reckamp, K. | Lin, H. | Huang, J. | +6